Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 24th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems Barcelona, Spain.

Day 1 :

  • Novel Drug Delivery Systems
Location: Webinar

Session Introduction

Manas Sahoo

Pharm, AVN Ayurveda Formulation Pvt Ltd -India

Title: Lignocellulosic Fibrous Reinforcements For Sustainable Polymeric Composites
Biography:

Mana’s has his expertise In Natural Product chemistry, structure elucidation, Herbal Drug and Traditional Medicine, Ethno medicine, Quality control and evaluation of various botanicals and herbal drug raw materials. He has been well versed in development of various advance and generic formulation with herbal active ingredients in cosmetic and pharmaceutical formulations. He is having more than 16 years of versatile experience in the field of natural product based drug discovery, formulation development, active ingredient development from herbal sources for pharmaceutical drug discovery and cosmetic active ingredient development. He has worked in various well known FMCG and Pharmaceutical and Health care based industry in India.

Abstract:

The unprecedented outbreak of severe acute respiratory syndrome-2 (SARCoV-2) worldwide has been one of the most dangerous pandemics documented ever in human history with enormous loss of life succumb to death and infection approximately 626 million cases of infection and over 6.6 million deaths have been reported globally till date. The scientific community has made mountainous progress in therapeutics and prevention for the management of COVID-19, including the development of vaccines, monoclonal antibodies and antiviral drugs. Similar to the COVID-19 another challenging area is knocking the doors is the rise of anti-microbial resistance across the globe due to un- targetted and careless use of antibiotics for minor infections. So there is a huge demand of new drug molecules for fighting against the unmet odds the human is encountering today

Biography:

Beshir Bedru Nasir is a young clinical pharmacist, Lecturer and researcher at Addis Ababa University. He is an expertise on medication use Evaluation, monitoring treatment outcomes, optimization of medication selection and medication adherence to treatments. He has conducted several researches especially in epilepsy management in Ethiopia to optimize treatment outcomes of chronic diseases. Moreover, he has been teaching pharmacotherapy and provides clinical pharmacy services in collaboration to other healthcare providers at Tikor Anbessa Specialized Hospital. He is also interested to conducted researches on pharmaco-economics of different treatment regimens for developing countries like Ethiopia.
 

Abstract:

Ethiopia is among the high TB burden countries and COVID- 19 has overtaken every other health issue in resource-limited settings. Its impacts on TB care include increasing undiagnosed TB patients, medication adherence and increase resistance. Thus, assessing the impacts of COVID-19 on TB care is paramount to implement a unique program for the management of TB during COVID-19 pandemic. A mixed study design was employed among randomly selected 10 health centres and 3 hospitals in Addis Ababa Ethiopia. The study period was March 4/2020 to December 4/2020 while (March 4/2019 to December 4/2019) was used as a baseline. The quantitative data was collected from TB patients’ medical registry, laboratory registry and treatment follow-up chart. The qualitative data was collected using in-depth interviews.

Bhupendra Prajapati

Patel College of Pharmaceutical Education and Research, India

Title: Nanoemulsion concept for water-poor soluble to improve therapeutic benefit
Biography:

Dr.Bhupendra Prajapati is a Professor in Department of Pharmaceutics, Shree S.K.Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India. He has more than 20 years of academic and research experience, has published more than 100 research and review papers in international and national Journals. Under his editorial two book under process and he authored 20 book chapters in the field of novel drug delivery. He published two Indian patent and three applications under evaluation. He is a reviewer in three high impact journals and is on the editorial board of several scientific
 

Abstract:

nature of the majority of newly developed anticancer drugs has resulted in poor bioavailability and pharmacokinetic variations (BCS II or IV drugs). Nanoemulsion formulations are becoming an effective delivery system for poorly water-soluble drugs. The term "Nanoemulsion" refers to a thermodynamically stable isotropically clear dispersion of two immiscible liquids, such as oil and water, stabilized by an interfacial film of surfactant molecules. The Nanoemulsion is formed readily and sometimes spontaneously, generally without high-energy input. The method of preparation of nanoemulsion includes high-pressure homogenizer or ultrasonication or microfluidization as part of the high-energy method. In the low energy category or condensation method, scientists had applied phase transition and spontaneous emulsification

Speaker
Biography:

Dr. Sanad Alonezi received his PhD degree in Pharmaceutical sciences from university of Strathclyde in 2017 (UK). He is currently working as a consultant pharmacist at prince sultan military medical city (PSMMC). He has a strong interest in areas of research involve metabolomics and pharmaceutical analysis.

Abstract:

Coronavirus pandemic disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus that is accounted as global pandemic health concern. The most commonly COVID-19 symptoms include fever, dry cough, sore throat, and fatigue. Severe illness is more likely in elderly patients and those with certain underlying medical conditions. Treatment of COVID-19 is primarily supportive and the role of antivirals treatments (COVID-19 vaccines) have been approved. There are anti-COVID-19 drugs and vaccine. This review focuses on method of treatment COVID-19 and vaccine. Treatments methodology included antiviral drugs, monoclonal antibodies, symptom control and traditional medicine such as medicinal plant extracts. 

Biography:

Dr. Mahmoud Ahmed Senousy Hassan: Associate Professor and Head of Biochemistry Department, Egyptian Chinese University, Cairo, Egypt, and Associate Professor of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. I Published 22 research articles in international journals with high impact factor in biochemistry, molecular biology, genetics and epigenetics in several diseases, including cancer, neurodegenerative diseases, autoimmune diseases and inflammatory bowel diseases. In 2022, my h-index has been raised to 11 (Scopus) and i10 index to 12. I Reviewed 49 manuscripts for several international journals and participated in 14 thesis supervision.

Abstract:

Recently, the use of nanotechnology has boosted the prevention, diagnosis and treatment of breast cancer (BC) through enhancing the effectiveness of chemotherapeutic drugs and decreasing its toxicity as they can target tumor cells with high specificity. However; developing epigenetic drugs with nanoformulation for BC remains a novel therapeutic approach. Cromolyn is a mast cell stabilizer emerging as an anticancer drug; its encapsulation in chitosan nanoparticles (CSNPs) improves its effect and bioavailability. Howbeit, its effect on DNA and RNA methylation machineries has not been previously investigated. The possible anticancer effect of cromolyn CSNPs and its potential as an epigenetic drug was investigated in vitro using MCF-7 human BC cell line. Cromolyn CSNPs showed prominent anticancer effect in MCF-7 cells by reducing the cell viability percent and enhancing DNA damage in the comet assay demonstrating its apoptotic actions. Mechanistically, cromolyn CSNPs influenced potential epigenetic processes.